New hope for rare brain diseases: long-term drug trial now recruiting

NCT ID NCT07399704

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests the long-term safety and effectiveness of a daily medication called nizubaglustat in people with two rare genetic diseases that affect the brain and body. About 21 participants who were in a previous study or who have been on a similar drug (miglustat) will take nizubaglustat for up to several years. Researchers will monitor side effects, seizures, and disease markers to see if the drug helps control the condition over time.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GM2 GANGLIOSIDOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

GM2 gangliosidosis Niemann-Pick disease type C

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Associação Hospitalar de Prot à Infância Dr. Raul Carneiro

    RECRUITING

    Água Verde, Curitiba, 80250-060, Brazil

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Hospital de Clinicas de Porto Alegre

    RECRUITING

    Porto Alegre, Rio Grande do Sul, 90035-903, Brazil

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Instituto Nacional de Saúde da Mulher, da Criança e do Adolescente Fernandes Figueira

    RECRUITING

    Rio de Janeiro, 22250, Brazil

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact